![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 8
2019
Garlipp, B.; Gibbs, P.; Van Hazel, G. A.; Jeyarajah, R.; Martin, R. C. G.; Bruns, C. J.; Lang, H.; Manas, D. M.; Ettorre, G. M.; Pardo, F.; Donckier, V.; Benckert, C.; van Gulik, T. M.; Goere, D.; Schön, M.; Pratschke, J.; Bechstein, W. O.; de la Cuesta, A. M.; Adeyemi, S.; Ricke, J. und Seidensticker, M.
(2019):
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.
In: British Journal of Surgery, Bd. 106, Nr. 13: S. 1837-1846
2018
Modest, Dominik P.; Denecke, Timm; Pratschke, J.; Ricard, Ingrid; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, Markus; Seehofer, Daniel; Bruns, Christiane J.; Gebauer, B.; Modest, H. I.; Held, S.; Folprecht, Gunnar; Heinemann, Volker und Neumann, Ulf Peter
(2018):
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
In: European Journal of Cancer (EJC), Bd. 88: S. 77-86
2017
Modest, Dominik P.; Denecke, Timm; Pratschke, J.; Ricard, Ingrid; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Modest, H. I.; Held, S.; Folprecht, Gunnar; Heinemann, Volker und Neumann, Ulf Peter
(2017):
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
In: European Journal of Cancer, Bd. 88: S. 77-86
Modest, D. P.; Neumann, U. P. und Pratschke, J.
(2017):
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
In: European Journal of Cancer, Bd. 73: S. 71-73
Modest, D. P.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Stintzing, S.; Modest, H. I.; Held, S.; Folprecht, G.; Heinemann, V. und Neumann, U. P.
(2017):
Central evaluation for surgical treatment options in FIRE-3-updated results and impact on overall survival.
In: Oncology Research and Treatment, Bd. 40: S. 122
Herden, U.; Strassburg, C. P.; Schöning, W. N.; Pratschke, J.; Kalff, J. C.; Manekeller, S.; Paul, A.; Schnitzbauer, A.; Linke, R.; Lorf, T.; Lehner, F.; Braun, F.; Stippel, D. L.; Sucher, R.; Schmidt, H.; Guba, M.; Rosmalen, M. van; Rogiers, X.; Samuel, U. und Nashan, B.
(2017):
Retrospective Analysis Of The Current Situation Of Liver Transplantation For HCC In Germany With Special Regard To Pre- And Posttransplant Tumour Staging.
In: Transplant international, Bd. 30: S. 8
2016
Neumann, U.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Folprecht, G.; Stintzing, S.; Held, S.; Heinemann, V. und Modest, D. P.
(2016):
Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) - a retrospective, central evaluation of FIRE-3.
In: Annals of Oncology, Bd. 27
Ashraf, M. I.; Schwelberger, H. G.; Brendel, K. A.; Feurle, J.; Andrassy, J.; Kotsch, K.; Regele, H.; Pratschke, J.; Maier, H. T. und Aigner, F.
(2016):
Exogenous Lipocalin 2 Ameliorates Acute Rejection in a Mouse Model of Renal Transplantation.
In: American Journal of Transplantation, Bd. 16, Nr. 3: S. 808-820